title: The neurogenic bladder: medical treatment.
abstract: Neurogenic bladder sphincter dysfunction (NBSD) can cause severe and irreversible renal damage and bladder-wall destruction years before incontinence becomes an issue. Therefore, the first step in adequate management is to recognize early the bladder at risk for upper- and lower-tract deterioration and to start adequate medical treatment proactively. Clean intermittent catheterization combined with anticholinergics (oral or intravesical) is the standard therapy for NBSD. Early institution of such treatment can prevent both renal damage and secondary bladder-wall changes, thereby potentially improving long-term outcomes. In children with severe side effects or with insufficient suppression of detrusor overactivity despite maximal dosage of oral oxybutynin, intravesical instillation is an effective alternative. Intravesical instillation eliminates systemic side effects by reducing the first-pass metabolism and, compared with oral oxybutynin, intravesical oxybutynin is a more potent and long-acting detrusor suppressor. There is growing evidence that with early adequate treatment, kidneys are saved and normal bladder growth can be achieved in children so they will no longer need surgical bladder augmentation to achieve safe urinary continence in adolescence and adulthood.
authors: Department of Child Neurology, University Hospitals K.U. Leuven, Herestraat 49, Leuven, Belgium. carla.verpoorten@uzleuven.be
authors: Carla
authors: C
authors: Verpoorten
authors: Gunnar M
authors: GM
authors: Buyse
mesh_terms: D002648:Child; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000628:therapy*; D014546:Urinary Catheterization / Q000379:methods*; D014563:Urodynamics; D013520:Urologic Surgical Procedures / Q000379:methods*
chemical_list: D018680:Cholinergic Antagonists